Historical Valuation
Alzamend Neuro Inc (ALZN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -19.94. The fair price of Alzamend Neuro Inc (ALZN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.40
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Alzamend Neuro Inc (ALZN) has a current Price-to-Book (P/B) ratio of 1.65. Compared to its 3-year average P/B ratio of -17.48 , the current P/B ratio is approximately -109.45% higher. Relative to its 5-year average P/B ratio of -0.93, the current P/B ratio is about -276.89% higher. Alzamend Neuro Inc (ALZN) has a Forward Free Cash Flow (FCF) yield of approximately -81.08%. Compared to its 3-year average FCF yield of -120.76%, the current FCF yield is approximately -32.86% lower. Relative to its 5-year average FCF yield of -80.82% , the current FCF yield is about 0.32% lower.
P/B
Median3y
-17.48
Median5y
-0.93
FCF Yield
Median3y
-120.76
Median5y
-80.82
Competitors Valuation Multiple
AI Analysis for ALZN
The average P/S ratio for ALZN competitors is 11.93, providing a benchmark for relative valuation. Alzamend Neuro Inc Corp (ALZN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ALZN
1Y
3Y
5Y
Market capitalization of ALZN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ALZN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ALZN currently overvalued or undervalued?
Alzamend Neuro Inc (ALZN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -19.94. The fair price of Alzamend Neuro Inc (ALZN) is between to according to relative valuation methord.
What is Alzamend Neuro Inc (ALZN) fair value?
ALZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Alzamend Neuro Inc (ALZN) is between to according to relative valuation methord.
How does ALZN's valuation metrics compare to the industry average?
The average P/S ratio for ALZN's competitors is 11.93, providing a benchmark for relative valuation. Alzamend Neuro Inc Corp (ALZN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Alzamend Neuro Inc (ALZN) as of Jan 09 2026?
As of Jan 09 2026, Alzamend Neuro Inc (ALZN) has a P/B ratio of 1.65. This indicates that the market values ALZN at 1.65 times its book value.
What is the current FCF Yield for Alzamend Neuro Inc (ALZN) as of Jan 09 2026?
As of Jan 09 2026, Alzamend Neuro Inc (ALZN) has a FCF Yield of -81.08%. This means that for every dollar of Alzamend Neuro Inc’s market capitalization, the company generates -81.08 cents in free cash flow.
What is the current Forward P/E ratio for Alzamend Neuro Inc (ALZN) as of Jan 09 2026?
As of Jan 09 2026, Alzamend Neuro Inc (ALZN) has a Forward P/E ratio of -0.60. This means the market is willing to pay $-0.60 for every dollar of Alzamend Neuro Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Alzamend Neuro Inc (ALZN) as of Jan 09 2026?
As of Jan 09 2026, Alzamend Neuro Inc (ALZN) has a Forward P/S ratio of 0.00. This means the market is valuing ALZN at $0.00 for every dollar of expected revenue over the next 12 months.